Sector Update: Healthcare
Healthcare shares are flat in pre-market trade.
QLT Inc. (QLTI, QLT.TO) says the first patient has been dosed in the company's Phase IIa proof-of-concept trial of QLT091001 in adult subjects with Impaired Dark Adaptation, a condition that results in decreased ability to recover visual sensitivity in the dark after exposure to bright lights.
MiMedx Group ( MDXG ) said it plans to sell 5 million shares in a public offering and that underwriters will have a 30-day option to buy up to 750,000 additional shares to cover any overallotments.
The developer, maker and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane plans to use proceeds for product development, sales and marketing initiatives and general corporate purposes.
MDXG closed higher 1.90% on Friday.
Finally, Cyclacel Pharmaceuticals Inc. ( CYCC ), a drug developer focused in the treatment of cancer, announced new primary endpoint data from its Phase 2 trial of oral sapacitabine capsules, the company's lead product candidate, in older patients with myelodysplastic syndromes (MDS).